| Acute Leukemia |
1 |
1 |
| Remission |
0 |
0.86 |
| Biologic Therapy |
0 |
0.79 |
| Toxicology |
0 |
0.47 |
| Stem Cell Research and Therapy |
0 |
0.4 |
| Geriatrics |
0 |
0.25 |
| Concerns of Elderly |
0 |
0.23 |
| Cancer |
0 |
0.18 |
| Chemotherapy |
0 |
0.18 |
| Leukemia |
0 |
0.18 |
| Transplantation |
0 |
0.18 |
| Acute Lymphoblastic Leukemia |
0 |
0.99 |
| Tyrosine Kinase Inhibitor |
0 |
0.98 |
| Hypertension |
0 |
0.13 |
| Pain Management |
0 |
0.13 |
| Revenue and Practice Management |
0 |
0.13 |
| Dyspnea |
0 |
0.12 |
| Tyrosine Kinase |
0 |
0.12 |
| Blood |
0 |
0.06 |
| Central Nervous System |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Hematology |
0 |
0.06 |
| Hyperglycemia |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Pain |
0 |
0.06 |
| Residual Disease |
0 |
0.06 |
| T-Lymphocyte |
0 |
0.06 |